Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The principal objective of this multicenter, randomized, placebo-controlled trial is to
evaluate whether 4 weeks of treatment with aprepitant will improve nausea as compared with
placebo in patients with symptoms of chronic nausea and vomiting of presumed gastric origin.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)